Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 5,126 matching trials from the live ClinicalTrials.gov search.
Filters: San Francisco, California Clear all
Completed Phase 2 Interventional Results available

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

NCT01457118
View directory record Official record
Conditions
Malignant Solid Tumor
Interventions
NKTR-102 145 mg/m2, NKTR-102 120 mg/m2, NKTR-102 95 mg/m2, NKTR-102 50 mg/m2
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Whittier, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Nov 4, 2026, 4:28 AM EST
Completed Phase 4 Interventional Results available

Valganciclovir to Reduce T Cell Activation in HIV Infection

NCT00264290
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus Infections
Interventions
Valganciclovir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Nov 4, 2026, 4:28 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Learning From Online Video Education for Controlled Ovarian Stimulation

NCT02979990
View directory record Official record
Conditions
Self Efficacy
Interventions
Instructional Video, Control Video
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
20 Years to 43 Years · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Nov 4, 2026, 4:28 AM EST
Completed Phase 1 Interventional

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

NCT00006024
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
lomustine, temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Nov 4, 2026, 4:28 AM EST
Completed Phase 3 Interventional

Diabetes Support Project: Couples Intervention

NCT01017523
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Telephone support and behavior change, Diabetes self-management education
Behavioral · Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
21 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
San Francisco, California • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Nov 4, 2026, 4:28 AM EST
Completed Not applicable Interventional

A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.

NCT00000855
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 5 Days
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 4, 2026, 4:28 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297
View directory record Official record
Conditions
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Interventions
zanubrutinib, bendamustine, rituximab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
60 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
12
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 4, 2026, 4:28 AM EST
Active, not recruiting Phase 2 Interventional

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

NCT05323955
View directory record Official record
Conditions
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Interventions
Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab, Tucatinib
Drug
Lead sponsor
Carey Anders, M.D.
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 4, 2026, 4:28 AM EST
Completed Phase 4 Interventional

The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.

NCT00995878
View directory record Official record
Conditions
Symptomatic Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Interventions
Focused ultrasound (MRgFUS), Uterine artery embolization (UAE)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Nov 4, 2026, 4:28 AM EST
Recruiting No phase listed Observational

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

NCT06579417
View directory record Official record
Conditions
Prostate Cancer
Interventions
RSI MRI
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
San Diego, California • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Nov 4, 2026, 4:28 AM EST
Recruiting Phase 3 Interventional

Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

NCT06380517
View directory record Official record
Conditions
Amblyopia
Interventions
Luminopia, Eye Patch
Device · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
4 Years to 7 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
72
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 4, 2026, 4:28 AM EST
Completed Phase 1 Interventional

A Safety Study of SGN-LIV1A in Breast Cancer Patients

NCT01969643
View directory record Official record
Conditions
HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
Interventions
ladiratuzumab vedotin, Trastuzumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Nov 4, 2026, 4:28 AM EST
Recruiting Not applicable Interventional

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

NCT06263426
View directory record Official record
Conditions
Hiv
Interventions
HIV D-/R+
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 4, 2026, 4:28 AM EST
Recruiting Phase 4 Interventional

Decolonization to Reduce After-Surgery Events of Surgical Site Infection

NCT05586776
View directory record Official record
Conditions
Surgical Site Infection
Interventions
4% Chlorhexidine Gluconate, 2% Mupirocin, Soap Without Antiseptic Properties (Placebo), Placebo Nasal Ointment
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
2,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Orange, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 4, 2026, 4:28 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Daily Calorie or Alternate-day Calorie Reductions on Risk for Cardiovascular Disease and Cancer

NCT00467220
View directory record Official record
Conditions
Moderately Overweight Individuals
Interventions
calorie restriction
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Nov 4, 2026, 4:28 AM EST
Active, not recruiting Phase 3 Interventional

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

NCT06531824
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 690517, Placebo matching BI 690517, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
8,371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
53
States / cities
Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 4:28 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)

NCT05823766
View directory record Official record
Conditions
Traumatic Brain Injury, Post-traumatic Epilepsy
Interventions
In-Person Outcome Assessment, 3T Magnetic Resonance Imaging (MRI), Clinical Visit, Blood Draw, EEG, Telephone Outcome Assessment
Behavioral · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
9
States / cities
San Francisco, California • Charlestown, Massachusetts • Cincinnati, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 4, 2026, 4:28 AM EST
Completed Phase 1Phase 2 Interventional Results available

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

NCT01512251
View directory record Official record
Conditions
BRAF Mutant Metastatic Melanoma
Interventions
BKM120 Combined with Vemurafenib (PLX4032)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Nov 4, 2026, 4:28 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)

NCT05444894
View directory record Official record
Conditions
Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia
Interventions
EDIT-301
Genetic
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Oakland, California • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Nov 4, 2026, 4:28 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Diabetes and Depression Text Messaging Intervention

NCT03490253
View directory record Official record
Conditions
Diabetes, Depression, Physical Activity
Interventions
DIAMANTE Adaptive, DIAMANTE Static
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Nov 4, 2026, 4:28 AM EST
Completed No phase listed Observational

Abbott i-STAT High Sensitivity Troponin I Study

NCT05629572
View directory record Official record
Conditions
Myocardial Infarction
Interventions
i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity
Diagnostic Test
Lead sponsor
Abbott Point of Care
Industry
Eligibility
18 Years and older
Enrollment
3,697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
28
States / cities
Chandler, Arizona • San Francisco, California • Stanford, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 4, 2026, 4:28 AM EST
Completed Phase 2 Interventional Results available

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

NCT03570619
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer, Solid Tumor
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Nov 4, 2026, 4:28 AM EST
Completed No phase listed Observational

Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythematosus

NCT00582465
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
7 Years to 22 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Nov 4, 2026, 4:28 AM EST
Completed Not applicable Interventional Results available

An Anesthesia-Centered Bundle to Reduce Postoperative Pulmonary Complications: The PRIME-AIR Study

NCT04108130
View directory record Official record
Conditions
Postoperative Pulmonary Complications
Interventions
Preoperative Education, Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization, Individualization of Neuromuscular Blockade, Postoperative Incentive Spirometry, Postoperative Ambulation
Other · Procedure · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Nov 4, 2026, 4:28 AM EST